MPM Bioimpact LLC Trims Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

MPM Bioimpact LLC lessened its position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 24.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,106,851 shares of the company's stock after selling 358,950 shares during the quarter. MPM Bioimpact LLC owned about 1.55% of Zentalis Pharmaceuticals worth $3,354,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Voya Investment Management LLC grew its stake in Zentalis Pharmaceuticals by 14.1% during the 4th quarter. Voya Investment Management LLC now owns 57,017 shares of the company's stock worth $173,000 after buying an additional 7,058 shares during the last quarter. Wells Fargo & Company MN grew its stake in Zentalis Pharmaceuticals by 26.8% during the 4th quarter. Wells Fargo & Company MN now owns 34,609 shares of the company's stock worth $105,000 after buying an additional 7,305 shares during the last quarter. Corton Capital Inc. purchased a new position in Zentalis Pharmaceuticals during the 4th quarter worth approximately $32,000. Northern Trust Corp grew its stake in Zentalis Pharmaceuticals by 2.2% during the 4th quarter. Northern Trust Corp now owns 484,738 shares of the company's stock worth $1,469,000 after buying an additional 10,513 shares during the last quarter. Finally, Federated Hermes Inc. increased its holdings in shares of Zentalis Pharmaceuticals by 2.2% in the fourth quarter. Federated Hermes Inc. now owns 493,982 shares of the company's stock valued at $1,497,000 after purchasing an additional 10,644 shares during the period.

Insider Activity

In other Zentalis Pharmaceuticals news, Director Scott Dunseth Myers bought 21,000 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Wednesday, April 30th. The shares were purchased at an average cost of $1.40 per share, for a total transaction of $29,400.00. Following the completion of the transaction, the director now owns 281,192 shares of the company's stock, valued at $393,668.80. This represents a 8.07% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.90% of the company's stock.

Wall Street Analysts Forecast Growth

ZNTL has been the topic of a number of recent research reports. HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a report on Thursday. Wells Fargo & Company dropped their target price on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating on the stock in a report on Thursday, January 30th. UBS Group dropped their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. Finally, Wedbush reissued a "neutral" rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a report on Thursday. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $8.24.

Zentalis Pharmaceuticals Price Performance

ZNTL remained flat at $1.26 during trading on Friday. The company's stock had a trading volume of 410,314 shares, compared to its average volume of 1,551,140. The stock's 50-day moving average price is $1.44 and its 200 day moving average price is $2.33. The firm has a market capitalization of $90.66 million, a P/E ratio of -0.51 and a beta of 1.81. Zentalis Pharmaceuticals, Inc. has a one year low of $1.01 and a one year high of $13.00.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, hitting analysts' consensus estimates of ($0.67). Equities research analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.